Association of Lipid Mediators With Development of Future Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population.
Adult
Aged
Anti-Citrullinated Protein Antibodies
/ immunology
Arthritis, Rheumatoid
/ epidemiology
Autoimmunity
/ immunology
Cohort Studies
Disease Progression
Docosahexaenoic Acids
/ metabolism
Family
Fatty Acids, Unsaturated
/ metabolism
Female
Humans
Hydroxyeicosatetraenoic Acids
/ metabolism
Incidence
Interleukin-1beta
/ immunology
Interleukin-6
/ immunology
Interleukin-8
/ immunology
Male
Mediation Analysis
Middle Aged
Multivariate Analysis
Proportional Hazards Models
Prospective Studies
Tumor Necrosis Factor-alpha
/ immunology
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
18
05
2020
accepted:
23
12
2020
pubmed:
1
1
2021
medline:
13
8
2021
entrez:
31
12
2020
Statut:
ppublish
Résumé
To determine the association of polyunsaturated fatty acid (PUFA)-derived lipid mediators with progression from rheumatoid arthritis (RA)-related autoimmunity to inflammatory arthritis (IA). We conducted a prospective cohort study using data from the Studies of the Etiology of Rheumatoid Arthritis (SERA). SERA enrolled first-degree relatives (FDRs) of individuals with RA (FDR cohort) and individuals who screened positive for RA-related autoantibodies at health fairs (screened cohort). We followed up 133 anti-cyclic citrullinated peptide 3.1 (anti-CCP3.1)-positive participants, 29 of whom developed IA. Lipid mediators selected a priori were quantified from stored plasma samples using liquid chromatography tandem mass spectrometry. We fit multivariable Cox proportional hazards models for each lipid mediator as a time-varying variable. For lipid mediators found to be significantly associated with IA, we then examined interleukin-1β (IL-1β), IL-6, IL-8, and tumor necrosis factor (TNF) as potential statistical mediators. For every 1 natural log pg/ml increase in the circulating plasma levels of proinflammatory 5-HETE, the risk of developing IA increased by 241% (hazard ratio 2.41 [95% confidence interval 1.43-4.07]) after adjusting for age at baseline, cohort (FDR or screened), and shared epitope status. The models examining 15-HETE and 17-HDHA had the same trend but did not reach significance. We did not find evidence that the association between 5-HETE and IA risk was influenced by the proinflammatory cytokines tested. In a prospective cohort of anti-CCP-positive individuals, higher levels of 5-HETE, an important precursor to proinflammatory leukotrienes, is associated with subsequent IA. Our findings highlight the potential significance of these PUFA metabolites in pre-RA populations.
Identifiants
pubmed: 33381911
doi: 10.1002/art.41631
pmc: PMC8169523
mid: NIHMS1657920
doi:
Substances chimiques
Anti-Citrullinated Protein Antibodies
0
CXCL8 protein, human
0
Fatty Acids, Unsaturated
0
Hydroxyeicosatetraenoic Acids
0
IL1B protein, human
0
IL6 protein, human
0
Interleukin-1beta
0
Interleukin-6
0
Interleukin-8
0
TNF protein, human
0
Tumor Necrosis Factor-alpha
0
Docosahexaenoic Acids
25167-62-8
5-hydroxy-6,8,11,14-eicosatetraenoic acid
467RNW8T91
15-hydroxy-5,8,11,13-eicosatetraenoic acid
73945-47-8
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid
90780-52-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
955-962Subventions
Organisme : NIAMS NIH HHS
ID : K23 AR051461
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI101981
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR007534
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR051394
Pays : United States
Informations de copyright
© 2020, American College of Rheumatology.
Références
Ann Rheum Dis. 2013 Jun;72(6):901-7
pubmed: 22915618
Ann Rheum Dis. 2003 Jun;62(6):501-9
pubmed: 12759283
Arthritis Rheum. 2010 Nov;62(11):3161-72
pubmed: 20597112
JCI Insight. 2016 Apr 21;1(5):e85922
pubmed: 27158677
Ann Rheum Dis. 2018 Jul;77(7):981-987
pubmed: 29436473
Ann Rheum Dis. 2007 Jun;66(6):712-9
pubmed: 16901957
Circ Res. 2020 Jan 3;126(1):75-90
pubmed: 31829100
Curr Top Med Chem. 2011;11(6):629-47
pubmed: 21261595
Ann Rheum Dis. 2008 Jun;67(6):860-6
pubmed: 17644543
Arthritis Rheum. 1998 Oct;41(10):1748-59
pubmed: 9778216
J Immunol. 2016 Sep 15;197(6):2362-8
pubmed: 27534559
Arthritis Rheum. 2010 Feb;62(2):383-91
pubmed: 20112361
Rheumatology (Oxford). 2017 Dec 1;56(12):2229-2236
pubmed: 29029330
Toxicol Sci. 2018 Jun 1;163(2):466-477
pubmed: 29471542
J Rheumatol. 2007 Nov;34(11):2144-53
pubmed: 17918787
Nat Rev Immunol. 2016 Jan;16(1):51-67
pubmed: 26688348
J Thromb Haemost. 2015 Jun;13(6):893-908
pubmed: 25900780
Science. 2010 Jan 29;327(5965):580-3
pubmed: 20110505
Mol Aspects Med. 2017 Dec;58:57-64
pubmed: 28456616
Immunity. 2014 Mar 20;40(3):315-27
pubmed: 24656045
J Clin Invest. 2001 Dec;108(12):1745-7
pubmed: 11748257
Arthritis Res Ther. 2015 Aug 24;17:209
pubmed: 26268317
J Immunol. 2014 Oct 1;193(7):3769-78
pubmed: 25172497
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Feb 15;1076:35-43
pubmed: 29396366
Curr Rheumatol Rep. 2014 May;16(5):419
pubmed: 24643396
Biochim Biophys Acta. 2012 Nov;1821(11):1415-24
pubmed: 22841830
J Leukoc Biol. 2019 Aug;106(2):241-257
pubmed: 30576001
PLoS One. 2012;7(5):e35296
pubmed: 22662108
Arthritis Rheum. 2009 Dec 15;61(12):1735-42
pubmed: 19950324
Front Immunol. 2019 Sep 27;10:2241
pubmed: 31611873
Arthritis Rheum. 2009 Mar;60(3):641-52
pubmed: 19248103
J Immunol. 2010 Jun 1;184(11):6418-26
pubmed: 20435922
Neuroscience. 2014 Jul 25;273:65-78
pubmed: 24836854
Kidney Int. 1995 May;47(5):1295-302
pubmed: 7543622
Arthritis Rheum. 2008 Jan;58(1):15-25
pubmed: 18163481
Sci Rep. 2019 Aug 19;9(1):12033
pubmed: 31427689
Rheum Dis Clin North Am. 2010 May;36(2):213-41
pubmed: 20510231